Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.
复制标题
DOI：
10.1182/bloodadvances.2021005094
复制
发表时间：
2021-08-24
期刊：
影响因子：
7.5
通讯作者：
Avivi I
中科院分区：
文献类型：
--
作者：
Perry C;Luttwak E;Balaban R;Shefer G;Morales MM;Aharon A;Tabib Y;Cohen YC;Benyamini N;Beyar-Katz O;Neaman M;Vitkon R;Keren-Khadmy N;Levin M;Herishanu Y;Avivi I
接受抗CD 20抗体治疗的B-NHL患者不太可能对BNT 162 b2 mRNA COVID-19疫苗产生体液反应。自上次暴露于抗CD20抗体以来的时间越长，预测应答率越高，抗体滴度也越高。诊断为B细胞非霍奇金淋巴瘤（B-NHL）的患者，特别是最近接受抗CD20抗体治疗的患者，有患严重COVID-19疾病的风险。由于缺乏评估这些患者对COVID-19疫苗的体液反应的研究，因此有关疫苗接种策略的建议仍不清楚。在间隔21天接受2剂疫苗的B-NHL患者中评估了对BNT162b2信使RNA（mRNA）COVID-19疫苗的体液免疫应答，并与健康对照组的应答进行了比较。在第二次疫苗接种后2至3周，评价通过Elecsys Anti-SARS-CoV-2S测定法测量的抗体滴度。评估了B-NHL（n = 149）、侵袭性B-NHL（a-B-NHL; 47%）或惰性B-NHL（i-B-NHL; 53%）患者。28例（19%）为初治，37%积极接受基于利妥昔单抗/obinutuzumab（R/Obi）的诱导方案或R/Obi维持治疗，44%在接种疫苗前接受过R/Obi治疗> 6个月。血清反应阳性率分别为89%、7.3%和66.7%，B-NHL患者的反应率为49%，而65名健康对照者的反应率为98.5%（P <0.001）。多变量分析显示，自接触R/Obi以来的时间较长且绝对淋巴细胞计数≥ 0.9 × 103/μ L，预示着血清学反应呈阳性。抗CD20抗体治疗的患者中，i-B-NHL与a-B-NHL相比，达到血清学阳性的中位时间更长。正在接受R/Obi治疗的B-NHL患者对BNT162b2 mRNA COVID-19疫苗的体液反应受损。自暴露于R/Obi以来的时间越长，对COVID-19疫苗的应答率越高。本研究在www.example.com注册为#NCT 04746092。
Patients with B-NHL treated with an anti-CD20 antibody are unlikely to achieve humoral response to BNT162b2 mRNA COVID-19 vaccine. Longer time since last exposure to anti-CD20 antibodies predicts a higher response rate and elevated antibody titer. Patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies evaluating humoral response to COVID-19 vaccine in these patients are lacking, recommendations regarding vaccination strategy remain unclear. The humoral immune response to BNT162b2 messenger RNA (mRNA) COVID-19 vaccine was evaluated in patients with B-NHL who received 2 vaccine doses 21 days apart and compared with the response in healthy controls. Antibody titer, measured by the Elecsys Anti-SARS-CoV-2S assay, was evaluated 2 to 3 weeks after the second vaccine dose. Patients with B-NHL (n = 149), aggressive B-NHL (a-B-NHL; 47%), or indolent B-NHL (i-B-NHL; 53%) were evaluated. Twenty-eight (19%) were treatment naïve, 37% were actively treated with a rituximab/obinutuzumab (R/Obi)–based induction regimen or R/Obi maintenance, and 44% had last been treated with R/Obi >6 months before vaccination. A seropositive response was achieved in 89%, 7.3%, and 66.7%, respectively, with response rates of 49% in patients with B-NHL vs 98.5% in 65 healthy controls (P < .001). Multivariate analysis revealed that longer time since exposure to R/Obi and absolute lymphocyte count ≥0.9 × 103/μL predicted a positive serological response. Median time to achieve positive serology among anti-CD20 antibody-treated patients was longer in i-B-NHL vs a-B-NHL. The humoral response to BNT162b2 mRNA COVID-19 vaccine is impaired in patients with B-NHL who are undergoing R/Obi treatment. Longer time since exposure to R/Obi is associated with improved response rates to the COVID-19 vaccine. This study is registered at www.clinicaltrials.gov as #NCT04746092.
登录
查看更多内容
全国多中心对七种血清学检测方法的比较显示，SARS-CoV-2 的血清学检测结果显示，有一部分人血清学检测结果为阴性。
影响因子：
15.1
作者：
Oved K;Olmer L;Shemer-Avni Y;Wolf T;Supino-Rosin L;Prajgrod G;Shenhar Y;Payorsky I;Cohen Y;Kohn Y;Indenbaum V;Lazar R;Geylis V;Oikawa MT;Shinar E;Stoyanov E;Keinan-Boker L;Bassal R;Reicher S;Yishai R;Bar-Chaim A;Doolman R;Reiter Y;Mendelson E;Livneh Z;Freedman LS;Lustig Y
通讯作者：
Lustig Y
影响因子：
5.5
作者：
Brydak, Lidia B.;Machala, Magdalena;Bilinski, Przemyslaw
通讯作者：
Bilinski, Przemyslaw
影响因子：
32.4
作者：
Bonifacius A;Tischer-Zimmermann S;Dragon AC;Gussarow D;Vogel A;Krettek U;Gödecke N;Yilmaz M;Kraft ARM;Hoeper MM;Pink I;Schmidt JJ;Li Y;Welte T;Maecker-Kolhoff B;Martens J;Berger MM;Lobenwein C;Stankov MV;Cornberg M;David S;Behrens GMN;Witzke O;Blasczyk R;Eiz-Vesper B
通讯作者：
Eiz-Vesper B
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
20.3
作者：
Herishanu Y;Avivi I;Aharon A;Shefer G;Levi S;Bronstein Y;Morales M;Ziv T;Shorer Arbel Y;Scarfò L;Joffe E;Perry C;Ghia P
通讯作者：
Ghia P